Pipamperone is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia. Pipamperone acts as an antagonist of the 5-HT2A, 5-HT2B, 5-HT2C D2, D3, D4, α1-adrenergic, and α2-adrenergic receptors. It shows much higher affinity for the 5-HT2A and D4 receptors over the D2 receptor (15-fold in the case of the D4 receptor, and even higher in the case of the 5-HT2A receptor), being regarded as 'highly selective' for the former two sites at low doses. Pipamperone has low and likely insignificant affinity for the H1 and mACh receptors, as well as for other serotonin and dopamine receptors. References: Boettger S, Knopfel S, Schubert M, Garcia Nunez D, Plichta MM, Klaghofer R, Jenewein J. Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes. Swiss Med Wkly. 2017 Jul 27;147:w14471. doi: 10.4414/smw.2017.14471. eCollection 2017 Jul 27. PubMed PMID: 28750419.

纯度：≥98%

CAS：1893-33-0